Skip to main content
. Author manuscript; available in PMC: 2013 Nov 15.
Published in final edited form as: Cancer Res. 2013 Mar 27;73(10):3041–3050. doi: 10.1158/0008-5472.CAN-12-3947

Figure 5.

Figure 5

IGF2BP2 binds to mRNAs and regulates multiple oncogenic genes, including NRAS. A, IGF2BP2 binds to mRNAs of Igf2, Ccnd2, NRas, Ran, RhoA, and Sp1, but not GAPDH, MYOD, and HMGA2. **, P < 0.01, Student t test, IGF2BP2 antibody versus IgG control. B, IGF2BP2 binds to the 3′UTR of NRAS mRNA. C, IGF2BP2 regulates the stability of NRAS mRNA. After IGF2BP2 shRNA treatment, NRAS mRNA half-life (T1/2) is reduced from 6.3 to 3.9 hours. HMGA2 shRNA reduces half-life to 3.5 hours. D, knockdown of IGF2BP2 reduces NRAS protein levels. Five different shRNAs were used to knock down IGF2BP2; NRAS protein levels correlate well with IGF2BP2 knockdown efficacy. E, knockdown of HMGA2 reduces the NRAS protein level in ERMS cells. F, IGF2BP2 stabilizes NRAS-3′UTR-luciferase protein. Luciferase assays show a dose-dependent increase of luciferase activity with IGF2BP2 overexpression. *, P < 0.01, Student t test.

HHS Vulnerability Disclosure